Medical Use
Isturisa is a medication that inhibits cortisol synthesis, used to treat adults with Cushing’s disease when pituitary surgery is not an option or has not been successful.
Recommended Dosage: Start with 2 mg taken orally twice daily, with or without food. Adjust the dose by 1-2 mg twice daily, no more frequently than every two weeks, based on cortisol level changes, individual tolerance, and improvement in Cushing’s disease symptoms. If a patient can tolerate 10 mg twice daily but still has elevated 24-hour urine free cortisol (UFC) levels, the dose can be increased by 5 mg twice daily every two weeks.
The maintenance dose of Isturisa is personalized, based on cortisol levels and the patient’s symptoms. In clinical trials, maintenance doses ranged from 2 mg to 7 mg twice daily. The maximum recommended maintenance dose is 30 mg twice daily. Once the maintenance dose is established, monitor cortisol levels every 30 to 60 days or as needed.
Warning & Precautions
Cortisol levels should be monitored using at least two 24-hour urine free cortisol collections every 1 to 2 weeks until a stable clinical response is achieved.
Treatment with Isturisa (10 mg or other dosages) typically reduces cortisol levels, which may lead to hypocortisolism and potentially severe adrenal insufficiency. Patients should be informed about the symptoms of hypocortisolism and advised to contact their doctor if these symptoms occur.
Isturisa (5 mg or other dosages) can cause dose-dependent QT interval prolongation, leading to cardiac arrhythmias. Extra caution is advised for patients with risk factors for QT prolongation, and more frequent ECG monitoring may be necessary.
Women should be advised not to breastfeed during treatment with Isturisa (1 mg, 5 mg, or 10 mg) and for at least seven days after the treatment ends.
Before starting Osilodrostat, correct any hypokalemia and hypomagnesemia. Obtain a baseline ECG and repeat it within 7 days after beginning treatment.
Documentation Availability
Documents required to import ISTURISA to India?
ISTURISA (Osilodrostat) tablets can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing ISTURISA (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for Isturisa®?
The generic name for Isturisa® is Osilodrostat.
Who manufactures Isturisa®?
Isturisa® is manufactured by Recordati Rare Diseases, Inc.
Is Isturisa® FDA approved?
Yes, Isturisa® was approved by the FDA on March 6, 2020.
What is Isturisa® used for?
Isturisa® (Osilodrostat) is the first cortisol synthesis inhibitor designed to treat Cushing’s disease in patients who cannot undergo pituitary surgery or for whom the surgery was ineffective.
What are the available dosages and forms of Isturisa®?
Isturisa® is available in tablet form with dosages of 1 mg, 5 mg, and 10 mg for oral administration.
What are the common side effects of Isturisa®?
Common side effects of Isturisa® include edema, adrenal insufficiency, fatigue, nausea, and headache.
How much does Isturisa® cost in India?
The cost of Isturisa® in India is considered reasonable. For authentic procurement, you can reach out to Rx4u team.
What are the storage conditions for Isturisa®?
Store Isturisa® tablets at a temperature between 68°F to 77°F (20°C to 25°C), with excursions permitted between 59°F to 86°F (15°C to 30°C). Protect the tablets from moisture.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
